# Briggs Morrison

> Briggs Morrison is a medical oncologist turned biopharma leader who runs Crossbow Therapeutics, a Cambridge, Massachusetts company building TCR-mimetic antibody drugs that aim T-cells at cancer targets once thought unreachable. Before Crossbow he ran late-stage R&D at the scale of an industry giant, serving as Chief Medical Officer and EVP of Global Medicines Development at AstraZeneca, and holding senior development roles at Pfizer and Merck across three decades. His fingerprints are on blockbuster cancer medicines including TAGRISSO and LYNPARZA. Today he splits his identity between operator and investor: CEO of Crossbow, Entrepreneur Partner at MPM BioImpact, and a fixture on biotech boards including chair of Arvinas.

- **Role:** President & CEO at Crossbow Therapeutics
- **Organizations:** Crossbow Therapeutics, MPM BioImpact, Arvinas, AstraZeneca (former), Pfizer (former), Merck & Co. (former), Syndax Pharmaceuticals (former CEO), Werewolf Therapeutics (board)
- **Nationality:** American
- **Education:** B.S. in Biology, Georgetown University, M.D., University of Connecticut School of Medicine, Residency, Internal Medicine, Massachusetts General Hospital, Fellowship, Medical Oncology, Dana-Farber Cancer Institute, Post-doctoral fellowship in Genetics (lab of Philip Leder), Harvard Medical School, Post-doctoral research (lab of Lee Nadler), Dana-Farber Cancer Institute
- **Known for:** Oversaw late-stage development of blockbuster cancer medicines including TAGRISSO and LYNPARZA at AstraZeneca, Built and led global late-stage development organizations at three major pharmaceutical companies, Chaired TransCelerate BioPharma, an industry consortium to improve clinical trial processes

## Career timeline

- **1995** — Joins Merck Research Laboratories, rising to VP, Clinical Sciences, Oncology
- **2007** — Appointed Head of Clinical Development at Pfizer
- **2012** — Becomes Chief Medical Officer and EVP, Global Medicines Development at AstraZeneca
- **2015** — Leaves AstraZeneca to become CEO of Syndax Pharmaceuticals
- **2022** — Becomes CEO of Crossbow Therapeutics, an MPM BioImpact portfolio company
- **2026** — Leads Crossbow's $77M Series B to advance TCR-mimetic T-cell engager pipeline

## Achievements

- Oversaw late-stage development of blockbuster cancer medicines including TAGRISSO and LYNPARZA at AstraZeneca
- Built and led global late-stage development organizations at three major pharmaceutical companies
- Chaired TransCelerate BioPharma, an industry consortium to improve clinical trial processes
- Serves as Chair of the Board of Arvinas
- Led Crossbow Therapeutics to a $77 million Series B in 2026

## Latest updates

- **2026-03** — Crossbow Therapeutics closed a $77 million Series B co-led by Taiho Ventures and Arkin Bio Capital to advance its T-Bolt pipeline.
- **2026-07** — Crossbow advancing CBX-250 through Phase 1 (CROSSCHECK-001) with data expected by end of 2026 and CBX-663 Phase 1 slated for Q3 2026.

## Links

- Website: https://crossbowtx.com
- LinkedIn: http://www.linkedin.com/in/briggs-morrison-581b7a6

---

Profile page: https://yespress.io/briggs-morrison
Published by YesPress — https://yespress.io
Last updated: 2026-07-02